This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Zacks Analyst Blog Highlights: Verona, Squibb, Protagonist and Amgen
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Verona, Squibb, Protagonist and Amgen
Protagonist Therapeutics Stalls Ulcerative Colitis Study
by Zacks Equity Research
Protagonist Therapeutics' (PTGX) shares plunge more than 50%, following discontinuation of a mid-stage study on its key ulcerative colitis candidate, PTG-100.
Why Global Blood Therapeutics (GBT) Could Be Positioned for a Slump
by Zacks Equity Research
It seems to be a wise decision for investors to drop Global Blood Therapeutics (GBT) stock considering its negative estimate revision, price depreciation as well as unfavorable Zacks rank.
BioDelivery Sciences (BDSI) in Focus: Stock Moves 5.1% Higher
by Zacks Equity Research
Shares of BioDelivery Sciences (BDSI) rose over 5% yesterday.
Geron (GERN) in Focus: Stock Moves 10.8% Higher
by Zacks Equity Research
Geron (GERN) was a big mover last session, as the company saw its shares rise nearly 11% on the day.
G1 Therapeutics (GTHX) in Focus: Stock Moves 8.9% Higher
by Zacks Equity Research
Shares of G1 Therapeutics (GTHX) rose nearly 9% yesterday.
BioTime, Inc. (BTX) Looks Good: Stock Adds 6% in Session
by Zacks Equity Research
BioTime (BTX) was a big mover last session, as the company saw its shares rise 6% on the day amid huge volumes.
Penumbra (PEN) Forms JV on Virtual Reality in Health Space
by Zacks Equity Research
Penumbra's (PEN) joint venture with Sixense Enterprises indicates formation of a leading digital health platform in the field of virtual reality technology.
New Products Aid Boston Scientific, LOTUS Relaunch Lag Ails
by Zacks Equity Research
Boston Scientific (BSX) grows on product launches and international expansion. LOTUS relaunch delay hurts sales.
Thermo Fisher Buys Phenom-World, Aids Analytical Instruments
by Zacks Equity Research
On completion of Phenom-World purchase, Thermo Fisher (TMO) plans to integrate the business into its Analytical Instruments segment.
PetMed Rides on Solid Reorders & New Orders Amid Competition
by Zacks Equity Research
PetMed (PETS) strives to implement several strategies to revitalize the top line, focusing on advertising efficiency to boost new order sales and shifting sales to higher margin items.
Dicerna Pharmaceuticals (DRNA) in Focus: Stock Moves 6.2% Higher
by Zacks Equity Research
Dicerna Pharmaceuticals (DRNA) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Pieris Pharmaceuticals (PIRS) Soars: Stock Adds 15.2% in Session
by Zacks Equity Research
Pieris Pharmaceuticals (PIRS) saw a big move last session, as its shares jumped more than 15% on the day, amid huge volumes.
PDL BioPharma, Inc. (PDLI) Jumps: Stock Rises 8.2%
by Zacks Equity Research
PDL BioPharma, Inc, (PDLI) was a big mover last session, as the company saw its shares more than 8% on the day amid huge volumes.
PDL BioPharma, Inc. (PDLI) Jumps: Stock Rises 8.2%
by Zacks Equity Research
PDL BioPharma, Inc. (PDLI) was a big mover last session, as the company saw its shares more than 8% on the day amid huge volumes.
The Zacks Analyst Blog Highlights: Halozyme Therapeutics, Protagonist Therapeutics, Aptose Biosciences and Pieris Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Halozyme Therapeutics, Protagonist Therapeutics, Aptose Biosciences and Pieris Pharmaceuticals
4 Top-Ranked Biotech Stocks Under $20 With Room for Growth
by Zacks Equity Research
We take a look at the biotech stocks with a potential for growth keeping in mind that the industry has witnessed a rebound in 2017 from last year's challenges.